Scope Biosciences secures €2.5 Million EIC-Transition grant to revolutionize Point-of-Care diagnostics with the CRISPR-Cas based scopeDx platform

Wageningen, The Netherlands – March 7th 2024, Scope Biosciences, a pioneering Dutch biotech firm, is thrilled to announce the award of a €2.5 million EIC Transition grant, a testament to its groundbreaking work in molecular diagnostics. This grant, an outcome of the successful ERC-Proof of Concept collaboration with Wageningen University initiated two years ago, will propel the development of the scopeDx platform—a comprehensive solution for point-of-care diagnostics that promisesextreme accuracy in an onsite setting.

Scope Biosciences stands at the forefront of molecular diagnostic innovation, harnessing the power of CRISPR-Cas for rapid, accurate onsite nucleic acid detection. The EIC Transition grant emphasizes the company’s commitment to advancing healthcare and agriculture diagnostics, providing a significant boost to the development of the scopeDx platform. This platform is designed to offer an unparalleled "sample to answer" solution, ensuring rapid, accurate, and accessible diagnostic services in various settings, from hospitals to remote clinics to greenhouses.

Scope Biosciences is a spinoff of Wageningen University’s Laboratory of Microbiology, which is at the foreground of CRISPR-Cas research.

Prof. dr. John van der Oost commented on this achievement: “This is another important milestone in the development of Scope Biosciences. It started just a few years ago with some wild ideas from a group of students in our lab. Since then, they worked hard to transform a small start-up into an independent company, well on its way to becoming a serious player in the field of diagnostics. It feels like a privilege to have played a modest role in this process.”